These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 72690)

  • 1. [A study on certain aspects of various kinds of serum protein in hyperthyroidism (author's transl)].
    Mitani H
    Nihon Naibunpi Gakkai Zasshi; 1977 Sep; 53(9):1065-81. PubMed ID: 72690
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endocrine ophthalmopathy in Graves disease during antithyroid drug therapy (author's transl)].
    Wuttke H; Schlieter D; Krück F
    Klin Wochenschr; 1979 Jan; 57(2):69-74. PubMed ID: 84095
    [No Abstract]   [Full Text] [Related]  

  • 3. [Correlation between the protein-bound iodine and butanol-extracted iodine in the blood serum of patients with diffuse toxic goiter during treatment with mercazolyl].
    Okulov VB
    Probl Endokrinol (Mosk); 1969; 15(4):5-8. PubMed ID: 4189655
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug therapy of hyperthyroidism (author's transl)].
    Baumann G
    Ther Umsch; 1973 Oct; 30(10):734-9. PubMed ID: 4126863
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of thyrotoxicosis with lithium carbonate.
    Lazarus JH; Richards AR; Addison GM; Owen GM
    Lancet; 1974 Nov; 2(7890):1160-3. PubMed ID: 4139588
    [No Abstract]   [Full Text] [Related]  

  • 6. Elevation of serum creatine kinase during treatment with antithyroid drugs in patients with hyperthyroidism due to Graves disease. A novel side effect of antithyroid drugs.
    Suzuki S; Ichikawa K; Nagai M; Mikoshiba M; Mori J; Kaneko A; Sekine R; Asanuma N; Hara M; Nishii Y; Yamauchi K; Aizawa T; Hashizume K
    Arch Intern Med; 1997 Mar; 157(6):693-6. PubMed ID: 9080924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recurrence rate following thyrostatic therapy of patients with hyperthyroidism and diffuse goiter (Graves' disease). Relation to the concentration of inorganic iodine in the plasma].
    Hansen PE
    Ugeskr Laeger; 1983 Mar; 145(13):980-2. PubMed ID: 6190284
    [No Abstract]   [Full Text] [Related]  

  • 8. A patient-specific treatment model for Graves' hyperthyroidism.
    Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
    Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dynamics of PBI behavior in blood serum of patients with Graves-Basedow disease and toxic nodular goiter during treatment with methimetazole].
    Jaruga-Dolińska E; Zembrzuska Z; Korman E
    Endokrynol Pol; 1971; 22(6):535-43. PubMed ID: 4110630
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum concentrations of adiponectin in patients with hyperthyroidism before and after control of thyroid function.
    Hsieh CJ; Wang PW
    Endocr J; 2008 Jul; 55(3):489-94. PubMed ID: 18469483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma glycerol and glycerol turnover during treatment of hyperthyroidism.
    Tibbling G; Cederquist E; Lundquist A
    Clin Chim Acta; 1969 Aug; 25(2):189-98. PubMed ID: 4184576
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves' Hyperthyroidism.
    Vos XG; Endert E; Zwinderman AH; Tijssen JG; Wiersinga WM
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1381-9. PubMed ID: 26863422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relation of TRH test to thyroidal suppression test by triiodothyronine in patients with hyperthyroidism under treatment with antithyroid drugs (author's transl)].
    Kuribayashi T; Yuji S; Yajima Y
    Nihon Naibunpi Gakkai Zasshi; 1975 Feb; 51(2):103-8. PubMed ID: 50954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the pituitary-thyroid axis in the drug therapy of hyperthyroidism].
    Uchiyama K
    Nihon Naibunpi Gakkai Zasshi; 1966 Nov; 42(8):884-99. PubMed ID: 4165941
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Morphology and function-based surgery in different forms of hyperthyroidism].
    Röher HD; Horster FA; Frilling A; Goretzki PE
    Chirurg; 1991 Mar; 62(3):176-81. PubMed ID: 1709844
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs.
    Gardner DF; Rothman J; Utiger RD
    Clin Endocrinol (Oxf); 1979 Dec; 11(6):585-94. PubMed ID: 93993
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
    Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
    J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Change in the course of drug therapy of hyperthyroidism?].
    Reinwein D
    Med Klin (Munich); 1994 Jul; 89(7):383-8. PubMed ID: 7523843
    [No Abstract]   [Full Text] [Related]  

  • 20. [Hyperthyroidism].
    Bürgi U; Maurer P
    Schweiz Rundsch Med Prax; 1994 Jan; 83(3):61-4. PubMed ID: 7507596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.